01
What changed in biotechnology regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
Nutromics received FDA breakthrough device designation in the U.S. during the week of September 11, 2026, for its wearable patch designed to monitor vancomycin levels in real time.
Read at medcitynews.com ↗03
The US Food and Drug Administration (FDA) has placed a clinical hold on enrollment for trials of Biohaven's epilepsy drug candidate, BHV-7000.
Read at fiercebiotech.com ↗04
On September 10, 2026, Bayer received approval for its drug Hyrnuo as a first-line treatment for non-small cell lung cancer (NSCLC).
Read at citeline.com ↗05
The National Commission into the Regulation of AI in Healthcare, led by Professors Alastair Denniston and Henrietta Hughes, published its recommendations on 10 September 2026 to improve AI regulation in the UK.
Read at gov.uk ↗06
Massachusetts Governor Maura Healey visited the MassBio headquarters in Cambridge, Massachusetts, on Wednesday, September 9, 2026.
Read at fiercebiotech.com ↗07
The US Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's drug camizestrant on September 8, 2026.
Read at fiercebiotech.com ↗08
The US Food and Drug Administration (FDA) is implementing stricter enforcement measures regarding clinical trial data originating from China and other foreign countries.
Read at citeline.com ↗8 of 12 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in biotechnology this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
GE HealthCare is reportedly in advanced talks to acquire the radiopharmaceutical developer Sofie Biosciences.
Read at fiercebiotech.com ↗10
In August 2026, Chinese advanced molecular therapy firms continued to secure significant investment funding.
Read at citeline.com ↗11
Multifamily developer LCOR acquired a life sciences development site at 309 East 94th Street in Manhattan's Upper East Side from Taconic Partners for $73 million.
Read at commercialobserver.com ↗12
Frazier Life Sciences has successfully raised over $1.1 billion for its public fund dedicated to small and midsize biotech companies.
Read at fiercebiotech.com ↗13
Solstice Oncology has raised $225 million in a series A funding round.
Read at fiercebiotech.com ↗14
Solstice Oncology has raised $225 million in a new funding round to advance an immuno-oncology drug.
Read at biopharmadive.com ↗15
Luma Group announced the final close of its inaugural venture capital fund dedicated to life sciences.
Read at fiercebiotech.com ↗16
BrainChild Bio has raised $116 million in Series A financing to fund a pivotal Phase II trial for its lead CAR T-cell therapy candidate, BCB-276.
Read at genengnews.com ↗8 of 17 funding and m&a events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What products launched in biotechnology this week?
Notable product launches, releases and platform updates from the week.
17
Revolution Medicines received regulatory approval for its RAS inhibitor drug, Rasonque, indicated for the treatment of advanced pancreatic cancer.
Read at fiercebiotech.com ↗18
The Advanced Research Projects Agency for Health (ARPA-H) has launched the $62.7 million ADVOCATE program to develop autonomous AI agents for heart failure care.
Read at fiercehealthcare.com ↗19
NVIDIA released the BioNeMo Inference Runtime (BioIR) to accelerate biomolecular structure-prediction models on NVIDIA GPUs.
Read at nvidia.com ↗20
Beeline, a spinout company from Bristol Myers Squibb, plans to advance its lead TLR7/8 inhibitor candidate into pivotal clinical trials for the treatment of lupus.
Read at citeline.com ↗21
On September 8, 2026, Google DeepMind launched AlphaGenome Atlas, a platform containing predictions for the molecular effects of 9 billion single-nucleotide variants in the human genome.
Read at deepmind.google ↗22
Celltrion showcased its Omlyclo treatment for chronic urticaria and allergic asthma at the 2026 European Respiratory Society Congress held in Barcelona, Spain, from September 5 to 9.
Read at thelec.net ↗6 of 10 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in biotechnology this week?
Earnings, guidance and other financial results reported this week.
23
Novartis experienced a significant decline in market capitalization of approximately $30 billion following the failure of its Phase III clinical trial for the drug candidate delpacibart etedesiran (del-desiran).
Read at genengnews.com ↗24
Novartis shareholders are expressing concern over the company's M&A strategy following the failure of the muscle-wasting drug del-desiran in a late-stage trial.
Read at pharmexec.com ↗What research was published in biotechnology this week?
New research findings and studies published this week.
25
Researcher Juan Manuel Vazquez from UC Berkeley conducted a study on bat DNA to understand the biological mechanisms of longevity and disease resistance.
Read at sciencedaily.com ↗26
Researchers from the Wellcome Sanger Institute, University of Cambridge, and University College London published a study in Nature Genetics on September 11, 2026, regarding the impact of cancer treatments on healthy tissue.
Read at genengnews.com ↗27
Disc Medicine presented Phase II clinical trial data for its investigational agent DISC-3405.
Read at citeline.com ↗28
Scientists at the University of Leeds, led by Dr. Simha Sridharan and Prof. Anwesha Sarkar, have developed an AI model capable of identifying plant proteins that function as emulsifiers.
Read at esmmagazine.com ↗29
Researchers from Georgia Tech and Vanderbilt University have developed a bone marrow-on-a-chip model to study the development and behavior of antibody-producing plasma cells.
Read at genengnews.com ↗30
Researchers at Cedars-Sinai Health Sciences University identified that the protein PD-L2 helps senescent cells evade the immune system, contributing to age-related dysfunction.
Read at genengnews.com ↗31
Cleveland Clinic, RIKEN, and IBM have been named finalists for the 2026 ACM Gordon Bell Prize for their quantum-HPC chemistry research.
Read at ibm.com ↗32
Novartis announced that its neuromuscular drug candidate delpacibart etedesiran failed the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1) after missing the primary endpoint of vHOT improvement.
Read at genengnews.com ↗8 of 33 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit biotechnology this week?
Incidents, outages and safety events reported this week.
33
Anthropic reported that its Threat Intelligence team thwarted multiple attempts by scientists to use the Claude AI model for biological weapons research over the past year.
Read at gizmodo.com ↗34
Anthropic reported on September 10, 2026, that it disrupted several attempts by researchers to use its Claude AI models for biological research potentially linked to biological weapons development.
Read at foxbusiness.com ↗35
Anthropic reported that it has disrupted multiple attempts to use its AI models, including Claude, for research related to biological weapons development over the past eight months.
Read at aljazeera.com ↗What partnerships were announced in biotechnology this week?
Partnerships, integrations and joint projects announced this week.
36
ProBioGen and Transgene have expanded their existing collaboration through a new license agreement for the AGE1.CR.pIX cell line.
Read at genengnews.com ↗37
Carelon Research, led by President Mark Cziraky, has entered into a partnership with Manifold to enable researchers to analyze Carelon's real-world data alongside third-party datasets.
Read at pharmexec.com ↗2 of 3 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What people moved in and out of biotechnology roles this week?
Executive appointments and departures reported this week.
38
In August 2026, the biopharmaceutical industry saw 12 companies announce workforce reductions affecting 526 employees, representing a 90% decrease compared to August 2025.
Read at biospace.com ↗39
The U.S. Food and Drug Administration (FDA) has appointed permanent leaders for its Center for Biologics Evaluation and Research (CBER) and Center for Drug Evaluation and Research (CDER).
Read at biopharmadive.com ↗40
On September 7, 2026, the U.S. Department of Health and Human Services (HHS) announced four permanent senior leadership appointments at the FDA.
Read at pharmexec.com ↗3 of 7 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What else happened in biotechnology this week?
Developments from the week that fit none of the other sections.
41
Patients from the United States are increasingly traveling to Shanghai, China, for CAR-T immunotherapy due to significantly lower costs and faster processing times.
Read at futurism.com ↗42
Bebop is expanding its dairy-free, plant-fat ice cream brand from Taiwan into the broader APAC market.
Read at foodnavigator.com ↗43
Nacho Quinones and Aisling O'Loughlin discuss the implementation of Synthetic Advisory Boards (S-ABs) in the biopharmaceutical industry as of September 2026.
Read at pharmexec.com ↗44
Chantal Dresner reports on how life sciences companies are shifting their AI strategy from simple automation to holistic workforce planning.
Read at biospace.com ↗45
The pharmaceutical industry faces significant manufacturing hurdles in the commercialization of personalized mRNA cancer vaccines.
Read at pharmavoice.com ↗5 of 13 other developments events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.